 MENLO PARK, Calif., June 15, 2021 GLOBE NEWSWIRE -- Corcept Therapeutics Incorporated NASDAQ: CORT, a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced that it has entered into an agreement with Sun Pharmaceutical Industries Limited and related entities Sun resolving patent litigation related to Korlym, Corcepts medication for the treatment of patients with Cushings syndrome. The litigation has been pending in the United States District Court for the District of New Jersey since 2019, shortly after Sun notified Corcept that it had submitted an Abbreviated New Drug Application ANDA to the United States Food and Drug Administration FDA seeking approval to market a generic version of Korlym. 